drugset / Trial / NCT06522737
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
RandomizedParallel-groupOpen-labelTreatment
Summary
The study will evaluate the progression-free survival benefit of duvelisib monotherapy as compared to investigator's choice of gemcitabine or bendamustine in participants with relapsed/refractory nodal T cell lymphoma with TFH phenotype.
Timeline
- Start
- 2025-05-19
- Primary completion
- 2028-02
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bendamustine | Small molecule | — | Intravenous |
| Subject | Duvelisib | Small molecule | — | Oral |
| Comparator | Gemcitabine | Small molecule | — | Intravenous |